LNP Core

The Core facilities are operated in collaboration between the Penn Institute for RNA Innovation and NSF AIRFoundry (NSF DBI-2400135)AIRFoundry logo

 

Goal

The LNP Core provides an integrated platform for LNP design, high-throughput formulation screening, scale-up, characterization, and surface functionalization. Users can systematically explore formulation space using highly automated microfluidic technologies, rapidly translating promising formulations from screening to larger-scale production.

LNP Services Offered (for information about mRNA production, visit mRNA Core:

  • mRNA encapsulation into lipid nanoparticles (LNPs), primarily using SM-102 and ALC-0315. Other non-proprietary lipids may be considered on a case-by-case basis.
  • Off-the-shelf LNPs such as empty LNPs and commonly requested reporters such as Luc, GFP and mCherry, in addition to other research tools (ovalbumin, IL-12, Cas9).
  • Surface modification of mRNA-LNPs to facilitate targeted delivery to specific tissues and cell types.
  • Fluorescent labeling of mRNA (such as Cy5.5), LNPs (such as DiL, DiO, DiI), and mRNA-LNPs (dual labelling) for nanoparticle tracking, biodistribution, and microscopy.
  • LNP characterization including particle size, polydispersity (PDI), particle count, and mRNA encapsulation efficiency.
  • High-Throughput LNP Formulation Screening: High-throughput screening of RNA-LNP formulations to rapidly evaluate a broad range of lipid compositions and formulation parameters. Variables include RNA type, buffer composition, lipid type, lipid ratios, and N:P ratios. Formulation screenings are fully programmable, enabling rapid and systematic exploration of formulation space to identify promising LNP candidates.

Highlighted Capabilities

Explore up to 96 LNP formulations in a single automated run. AIRFoundry's high-throughput microfluidic formulation platform independently programs RNA identity, lipid composition, lipid ratios, and N:P ratio, requiring as little as 20µg RNA per formulation.

 

AIRFoundry uses the InfiniFluidics High Throughput Formulation System (HTFS) to automatically generate distinct RNA-LNP formulations for high-throughput rapid screening of formulation conditions. RNA, lipids, lipid ratios, and N:P ratios can all be independently programmed, enabling up to 96 formulations to be generated directly from individual component stocks in a single run, with as little as 20µg of RNA per sample. Formulations are automatically dispensed into well plates for further downstream processing and analysis.
Infini Fluidics HTFS
The Ignite NanoAssemblr™, used for large-scale (>0.5mg) formulations, allows for consistent and reproducible formulation of LNPs with tunable size and properties.
nana machone
Ignite NanoAssemblr
LNPs formulated by our team are characterized using the plate-based Stunner combinatorial analysis platform (Unchained Labs), including particle size, polydispersity (PDI), RNA encapsulation efficiency, particle concentration, and aggregate detection. Users can directly access the Stunner for characterization of user-supplied LNPs. To request access, contact User Facility Director Ben Davis
stunner machine
Unchained Labs Stunner

Pricing 

Internal charges (University of Pennsylvania and Children’s Hospital of Philadelphia only):

  • Consultation to aid construction design, pricing information or experiment planning: complimentary 
  • mRNA (see mRNA Core): $1500/mg 
    • Minimum order: 100ug 
  • LNPs: $1000/mg
    • Minimum order: 100ug for off-the-shelf mRNA-LNP and 200ug for custom mRNA-LNP

External charges (Academic and corporate):

  • Consultation to aid construction design, pricing information or experiment planning: complimentary
  • IVT mRNA: $2500/mg
    • Minimum order: 100ug
  • LNPs: $1625/mg
    • Minimum order: 100ug for off-shelf mRNA-LNP and 500ug for custom mRNA-LNP


Contact Information

To explore how the Engineered mRNA, LNP and Targeted Nanomedicine core might be helpful to your project, or for pricing/quote, please contact Dr. Garima Dwivedi and Dr. Benjamin Davis to schedule an initial consultation.

Garima Dwivedi

Senior Research Investigator, Weissman Lab
Director, mRNA Core, Penn Institute of RNA innovation
4012, 1UCity Sq
25 N 38th St
Philadelphia PA 19104

Email: garima.dwivedi@pennmedicine.upenn.edu

 

Benjamin Davis

User Facility Director, AIRFoundry
4072, 1UCity Sq
25 N 38th St
Philadelphia PA 19104

Email: benjamin.davis@pennmedicine.upenn.edu

AIRFoundry

Group Lead